Skip to main content
Premium Trial:

Request an Annual Quote

Immune Analysis Company Surge Closes €7.5M Fundraising Round

NEW YORK – Precision medicine startup Surge announced Thursday that it closed a €7.5 million ($8.1 million) funding round led by Eurazeo.

Other investors included Kima, Teampact, and MH Innov', as well as Boutique Venture, HCVC, and 50 Partners Santé. Additionally, Surge received grants from BPI and the Future Investment Program, of which Surge was a laureate.

The Paris-based company plans to use the cash infusion to open SurgeLab, a laboratory designed to discover immune biomarkers, and to launch PreCyte, the company's blood-based assay for predicting surgical complications. Surge will also use the new funding to continue refining its artificial intelligence algorithms.

This is Surge's second funding round. The firm raised $2.6 million in 2022.

"Building on solid scientific and technical fundamentals, Surge has already demonstrated the relevance of its biomarker discovery platform to address concrete clinical needs and integrate precision medicine into surgical care," Maxime Huerre, VP of venture at Eurazeo, said in a statement.